The US Food and Drug Administration (FDA) has approved a new class of drugs for treatment of migraine. This drug acts by targeting calcitonin gene-related peptide (CGRP), whose levels are found to be elevated in blood serum during migraine attacks. The three approved molecules in this class are erenumab-aooe, fremanezumab-vfrm and galcanezumab-gnlm
390 Reached13 Comments11 Likes
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Young Girl Presented with Irritability and Abnormal Behavior
2250 Reached10 Comments4 Likes
Study to Test Tofacitinib Efficacy for Psoriatic Arthritis
446 Reached2 Comments4 Likes
Spinal Anesthesia in Elderly Patient
4197 Reached10 Comments7 Likes
Unconscious Male in ED following Loss of Motorcycle Control
828 Reached2 Comments2 Likes